Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia. Conference Paper uri icon



  • Venous thromboembolism (VTE), osteonecrosis of the jaw, renal failure, and anemia are all common complications of multiple myeloma therapy. Many of these adverse events have been documented only in the past 5 to 10 years, in conjunction with the introduction of a series of the newer therapies thalidomide, bortezomib, and lenalidomide. This article discusses these complications in detail and provides strategies for health care providers to best prevent, identify, and manage them. Preventive measures, such as VTE prophylaxis and appropriate dental hygiene, as well as patient education, dose adjustments, limited duration of drug treatment, and consideration of therapies that are associated with less burdensome adverse-event profiles, can contribute to substantially improved outcomes and quality of life.

publication date

  • February 1, 2010



  • Anemia
  • Antineoplastic Agents
  • Jaw Diseases
  • Kidney Diseases
  • Multiple Myeloma
  • Osteonecrosis
  • Venous Thromboembolism


Scopus Document Identifier

  • 77649139818

PubMed ID

  • 20141670

Additional Document Info


  • 8 Suppl 1